A2B530 Harnesses Unique Mechanism of Action to Integrate CAR

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.

Related Keywords

Massachusetts , United States , Tampa , Florida , Boston , New York , Kedar Kirtane , Dianem Simeone , Department Of Head , Perlmutter Cancer Center , Society For Immunotherapy Of Cancer , Pancreatic Cancer Center , Endocrine Oncology At Moffitt Cancer Center , Neck Endocrine Oncology , Moffitt Cancer Center , Annual Meeting , Tmodt Cell , Accessed April , Cart Cell Therapies Observed In Patients With Hematologic Malignancies , Basecamp 1 Trial , Patients With Advanced Solid Tumors , Everest Trial ,